A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis
Status:
Completed
Trial end date:
2004-05-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy, safety, and tolerability of intramuscular ziprasidone in the
treatment of the acute exacerbation of non-organic psychosis of any etiology, including
schizophrenia, acute mania, delusional disorder and others.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.